| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/08/2013 | CA2598605C Controlled release oral delivery systems |
| 01/08/2013 | CA2579220C Pharmaceutical composition for the sustained release of hydralazine and use thereof as a support for cancer treatment |
| 01/08/2013 | CA2569514C Oral preparations and process for production thereof |
| 01/08/2013 | CA2562081C Method for encapsulation of orally ingested materials to alter the site of digestion, site of action, or stability |
| 01/08/2013 | CA2560468C Temperature sensitive polymers |
| 01/08/2013 | CA2546115C Solid dispersions or solid dispersion pharmaceutical preparations of phenylalanine derivatives |
| 01/08/2013 | CA2545513C Solid pharmaceutical preparation form |
| 01/08/2013 | CA2544291C Transdermal drug delivery method and system |
| 01/08/2013 | CA2530811C Zeolites for delivery of nitric oxide |
| 01/08/2013 | CA2513260C Oral compositions of fenretinide having increased bioavailability and methods of using the same |
| 01/08/2013 | CA2504608C Controlled release depot formulations |
| 01/08/2013 | CA2501201C Gastric acid secretion inhibiting composition |
| 01/08/2013 | CA2490121C Modified phospholipids |
| 01/08/2013 | CA2468539C Delivery of medicaments to the nail |
| 01/08/2013 | CA2466148C Medical compositions for intravesical treatment of bladder cancer |
| 01/08/2013 | CA2428782C Medicine based on anti-hyperglycaemic microcapsules with prolonged release and its method of preparation |
| 01/08/2013 | CA2414064C Clear aqueous anaesthetic composition |
| 01/08/2013 | CA2385498C Method to enhance healing of sternum after sternotomy |
| 01/08/2013 | CA2341352C Oral vaccine compositions |
| 01/08/2013 | CA2285394C Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases |
| 01/08/2013 | CA2224702C Stable hydroalcoholic compositions |
| 01/03/2013 | WO2013003845A1 Abuse resistant drug forms |
| 01/03/2013 | WO2013003827A2 Macrogol 15 hydroxystearate formulations |
| 01/03/2013 | WO2013003803A1 Topical formulations including lipid microcapsule delivery vehicles and their uses |
| 01/03/2013 | WO2013003622A1 Dosage forms for oral administration and methods of treatment using the same |
| 01/03/2013 | WO2013003491A1 Toroidal pharmaceutical formulations |
| 01/03/2013 | WO2013003114A1 Esters for treatment of ocular inflammatory conditions |
| 01/03/2013 | WO2013003113A1 Esters for treatment of ocular inflammatory conditions |
| 01/03/2013 | WO2013002892A1 Flat self-curling permeable sheet membrane |
| 01/03/2013 | WO2013002636A1 Controlled release system |
| 01/03/2013 | WO2013002505A1 Tape-type fluorine preparation using a biodegradable polymer material, and method for producing same |
| 01/03/2013 | WO2013002479A2 Nanoemulsion composition and method for preparing same |
| 01/03/2013 | WO2013002382A1 Nicorandil-containing pharmaceutical composition |
| 01/03/2013 | WO2013002317A1 Solid oxidized glutathione salt and method for producing same |
| 01/03/2013 | WO2013001543A1 An optimized bilayered tablet dosage form with two active antibiotics: clavulanic acid and cefpodoxime |
| 01/03/2013 | WO2013001542A1 An optimized bilayered tablet with two active antibiotics: cefadroxil and clavulanic acid |
| 01/03/2013 | WO2013001541A1 An optimized bilayered tablet dosage form with high rate of bioavailability of two active antibiotics: cefuroxime and clavulanic acid |
| 01/03/2013 | WO2013001536A1 Stabilized topical formulations containing core-shell microcapsules |
| 01/03/2013 | WO2013001516A1 Multilayered dosage form |
| 01/03/2013 | WO2013001441A1 Dry formulations of febuxostat |
| 01/03/2013 | WO2013001167A1 Non-toxic compositions for decreasing the risk of cancer caused by oral microbes |
| 01/03/2013 | WO2013001124A1 Saccharide nanocompositions for vaccine release |
| 01/03/2013 | WO2013001073A1 A new stable anesthetic composition for reducing skin reactions |
| 01/03/2013 | WO2013001044A1 Method for preventing the unfolding of a (poly) peptide and/or inducing the (re- ) folding of a (poly) peptide |
| 01/03/2013 | WO2013001034A1 Novel stabilisation method for viruses or bacteria |
| 01/03/2013 | WO2013000917A1 Topical ophthalmological pharmaceutical composition containing regorafenib |
| 01/03/2013 | WO2013000909A1 Topical ophthalmological pharmaceutical composition containing sorafenib |
| 01/03/2013 | WO2013000876A1 An aqueous composition comprising a biological antigen and an acrylic acid polymer |
| 01/03/2013 | WO2013000778A1 Applicator system for applying a viscous liquid to the human skin |
| 01/03/2013 | WO2013000578A1 Controlled release oral dosage form comprising oxycodone |
| 01/03/2013 | WO2013000392A1 Aripiprazole type i microcrystal, aripiprazole solid preparation, and preparation method |
| 01/03/2013 | WO2013000391A1 Aripiprazole medicament formulation and preparation method therefor |
| 01/03/2013 | WO2012154942A3 Ceramide anionic liposome compositions |
| 01/03/2013 | WO2012153347A3 Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate |
| 01/03/2013 | WO2012150839A3 Method for microencapsulating phosphatidylserine |
| 01/03/2013 | WO2012149255A3 Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins |
| 01/03/2013 | WO2012149247A3 Tolerogenic synthetic nanocarrier compositions with transplantable graft antigens and methods of use |
| 01/03/2013 | WO2012142520A3 Unit dose form for oral administration |
| 01/03/2013 | WO2012141502A3 Controlled release type tablet containing aceclofenac |
| 01/03/2013 | WO2012136969A3 Ophthalmic treatments |
| 01/03/2013 | WO2012135337A3 Topical skin care formulations comprising plant extracts |
| 01/03/2013 | WO2012131104A3 Biodegradable compositions suitable for controlled release |
| 01/03/2013 | WO2012119781A3 Novel lipids, phospholipids, phospholipid and lipid compositions and their use |
| 01/03/2013 | WO2012107760A3 Layered bodies, compositions containing them and processes for producing them |
| 01/03/2013 | WO2012106665A3 Disialyllacto-n-tetraose (dslnt) or variants, isomers, analogs and derivatives thereof to prevent or inhibit bowel disease |
| 01/03/2013 | WO2012104576A3 Carotenoid particles and uses thereof |
| 01/03/2013 | WO2012085919A3 Method and system for drug delivery |
| 01/03/2013 | WO2012073170A3 Galenic composition suitable for administration to a non-human animal, uses thereof, and associated methods |
| 01/03/2013 | WO2012061480A3 Compositions and methods for the delivery of therapeutics |
| 01/03/2013 | WO2012012546A3 METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS |
| 01/03/2013 | WO2011121559A3 Stabilized antibody preparations and uses thereof |
| 01/03/2013 | WO2009125226A8 Pharmaceutical depot comprising n-{5-[(cyclopropylamino)carbonyl] -2-methylphenyl}-3-fluoro-4- (pyridin-2-ylmethoxy)benzamide |
| 01/03/2013 | US20130006351 Polymer coatings containing drug powder of controlled morphology |
| 01/03/2013 | US20130006350 Drug-delivery endovascular stent and method for treating restenosis |
| 01/03/2013 | US20130006182 Pharmaceutical compositions |
| 01/03/2013 | US20130005779 Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics |
| 01/03/2013 | US20130005714 Water-Soluble Meloxicam Granules |
| 01/03/2013 | US20130004651 Sustained drug release from body implants using nanoparticle-embedded polymeric coating materials |
| 01/03/2013 | US20130004595 Compositions and Methods for Treating Skin Conditions |
| 01/03/2013 | US20130004579 Use of Plant Lectins to Target Leukocytes |
| 01/03/2013 | US20130004578 Solid Pharmaceutical Dosage Formulation |
| 01/03/2013 | US20130004577 Coated tablet |
| 01/03/2013 | US20130004576 Rifaximin powder, process for preparing the same and controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect |
| 01/03/2013 | US20130004575 Controlled release formulations using intelligent polymers |
| 01/03/2013 | US20130004574 Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointensinal tract |
| 01/03/2013 | US20130004573 Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride |
| 01/03/2013 | US20130004572 Stable pharmaceutical composition and methods of using same |
| 01/03/2013 | US20130004571 Orally Effective Methylphenidate Extended Release Powder and Aqueous Suspension Product |
| 01/03/2013 | US20130004570 Nutritional supplement for use under physiologically stressful conditions |
| 01/03/2013 | US20130004569 Oral antimicrobial pharmaceutical compositions |
| 01/03/2013 | US20130004568 Methods of treating hypertriglyceridemia |
| 01/03/2013 | US20130004567 Methods of treating hypertriglyceridemia |
| 01/03/2013 | US20130004566 Methods of treating hypertriglyceridemia |
| 01/03/2013 | US20130004565 Proteolytic enzyme formulations |
| 01/03/2013 | US20130004564 Antimicrobial peptides |
| 01/03/2013 | US20130004563 Multiparticulate s-adenosylmethionine compositions and related methods |
| 01/03/2013 | US20130004562 Process for preparing purified nucleic acid and the use thereof |
| 01/03/2013 | US20130004561 Therapies for preventing or suppressing clostridium difficile infection |
| 01/03/2013 | US20130004560 Polymer Nanofilm Coatings |
| 01/03/2013 | US20130004557 Antimicrobial Resin Compositions |